Another CD38 mAb, isatuximab was approved in 2020, in combination with pomalidomide and dexamethasone for the treatment of adult patients with MM who have received more than two prior therapies, and, in 2021, for combination with carfilzomib and dexamethasone, for the treatment of adult patients with R/R MM who have received one to three prior lines of therapy [55,56]. This evidence concerns the gene CD38 and Miyoshi myopathy.